View Older Stories View More Recent Stories

May 23, 2023 04:05PM AgeX Therapeutics Announces Appeal of NYSE American Determination
May 12, 2023 04:05PM AgeX Therapeutics Reports First Quarter 2023 Financial Results
Apr 26, 2023 04:05PM AgeX Therapeutics Receives Stock Exchange Deficiency Letter
Mar 31, 2023 04:05PM AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results
Nov 25, 2022 03:41PM AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
Nov 10, 2022 04:05PM AgeX Therapeutics Reports Third Quarter 2022 Financial Results
Aug 12, 2022 04:05PM AgeX Therapeutics Reports Second Quarter 2022 Financial Results
May 18, 2022 08:34AM AgeX Therapeutics Inc. (AGE) Appoints Joanne Hackett as Board Chair
May 18, 2022 08:30AM Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors
May 13, 2022 04:05PM AgeX Therapeutics Reports First Quarter 2022 Financial Results
Mar 29, 2022 04:05PM AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results
Dec 14, 2021 08:30AM AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders
Nov 30, 2021 08:30AM AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001
Nov 23, 2021 04:12PM AgeX Therapeutics Inc. (AGE) Receives Stock Exchange Deficiency Letter
Nov 23, 2021 04:05PM AgeX Therapeutics Receives Stock Exchange Deficiency Letter
Nov 12, 2021 04:05PM AgeX Therapeutics Reports Third Quarter 2021 Financial Results
Aug 13, 2021 04:05PM AgeX Therapeutics Reports Second Quarter 2021 Financial Results
Jul 23, 2021 04:15PM AgeX Therapeutics Inc. (AGE) and LyGenesis Terminate Merger Negotiations
Jul 23, 2021 04:15PM AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
May 17, 2021 04:05PM AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
Mar 31, 2021 04:05PM AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update
Mar 12, 2021 08:00AM AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer
Mar 10, 2021 08:00AM AgeX Therapeutics to Collaborate with The Ohio State University to Generate Proof-of-Concept Animal Data for AgeX’s Brown Adipose Tissue (BAT) Cell Therapy Candidate for Diabetes and Obesity
Mar 8, 2021 08:08AM Lineage Cell Therapeutics (LCTX) Raises $35.9 Million From Sales of Marketable Securities Holdings and an At-the-Market Equity Offering
Mar 8, 2021 08:00AM Lineage Cell Therapeutics Raises $35.9 Million From Sales of Marketable Securities Holdings and an At-the-Market Equity Offering
Mar 2, 2021 08:00AM AgeX Therapeutics and LyGenesis to Negotiate Merger Agreement
Nov 16, 2020 04:05PM AgeX Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
Nov 4, 2020 04:05PM Lineage Cell Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
Oct 28, 2020 08:00AM AgeX Therapeutics Sublicenses Stem Cell Line ESI-053 to ImStem Biotechnology for Development of Cell Therapy Candidate IMS001 for COVID-19 and Acute Respiratory Distress Syndrome
Sep 9, 2020 08:00AM AgeX Therapeutics and Lineage Cell Therapeutics Announce Expansion of Agreement Related to ESI Clinical-grade Pluripotent Stem Cell Lines for Therapeutic Purposes
Sep 9, 2020 08:00AM Lineage Cell Therapeutics and AgeX Therapeutics Announce Expansion of Agreement Related to ESI Clinical-Grade Pluripotent Stem Cell Lines for Therapeutic Purposes
Aug 31, 2020 09:07AM Lineage Cell Therapeutics (LCTX) Receives $24.6 Million Payment From Juvenescence Ltd.
Aug 31, 2020 09:05AM Lineage Cell Therapeutics Receives $24.6 Million Payment From Juvenescence Ltd.
Aug 14, 2020 04:05PM AgeX Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update
Aug 6, 2020 04:05PM Lineage Cell Therapeutics Reports Second Quarter 2020 Financial Results and Provides Update on All Clinical Programs
Jun 16, 2020 08:07AM AgeX Therapeutics Inc. (AGE), Pluristyx Announce Pact to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications
Jun 16, 2020 08:00AM AgeX Therapeutics and Pluristyx Announce Manufacturing, Marketing, and Distribution Agreement to Expand Access to Clinical-Grade Human Pluripotent Stem Cells for Therapeutic Applications
Jun 5, 2020 04:16PM AgeX Therapeutics Inc. (AGE) Receives Stock Exchange Deficiency Letter
Jun 5, 2020 04:15PM AgeX Therapeutics Receives Stock Exchange Deficiency Letter
Jun 2, 2020 08:09AM AgeX Therapeutics Inc. (AGE), ImStem Biotechnology Sign Non-Binding LOI Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS
Jun 2, 2020 08:00AM AgeX Therapeutics and ImStem Biotechnology Sign Non-Binding Letter of Intent Regarding Investigational MSC Candidate IMS001 for COVID-19 and Other Causes of ARDS
May 29, 2020 08:00AM AgeX Therapeutics and Sernova to Collaborate to Engineer Universal Locally Immune Protected Cell Therapies for Type I Diabetes and Hemophilia A
May 21, 2020 08:30AM AgeX Therapeutics, Inc. Appoints Andrea Park as Chief Financial Officer
May 14, 2020 04:05PM AgeX Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 7, 2020 04:05PM Lineage Cell Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update
May 1, 2020 08:54AM AgeX Therapeutics Announces Reduction in Projected Cash Expenditures
Mar 30, 2020 05:40PM AgeX Therapeutics Reports Fourth Quarter and Annual 2019 Financial Results and Provides Business Update
Mar 20, 2020 09:02AM AgeX Therapeutics (AGE) Licensee ImStem Biotechnology Announces FDA has Lifted Hold and Cleared Investigational NDA for IMS001 for Treatment of MS
Mar 20, 2020 09:00AM AgeX Therapeutics Licensee ImStem Biotechnology Announces FDA has Lifted the Hold and Cleared the Investigational New Drug Application for IMS001 for the Treatment of Multiple Sclerosis
Feb 28, 2020 08:00AM AgeX Therapeutics Researchers Publish Paper on the Age Reprogramming of Super-Centenarian Cells
View More Recent Stories View Older Stories